3. When drug maker GlaxoSmithKline PLC launched Requip for restless-legs syndrome, few consumers had heard of the problem, and some physicians were skeptical that it even existed. Despite these problems, the drug is now very successful. Should the marketing of a health care product that is not immediately recognized as responding to a health care need

(a) have more government oversight and control or

(b) be left to allow market forces to decide its value?